Evidence map›Paper›PMID 41428959›Full record

ArticleACS infectious diseases2026

Modular Design of Mitochondrion-Targeted Iron Chelators Allows Highly Selective Antiparasitic Activity against Trypanosomes and Apicomplexan Parasites.

Ronald Malych, Yann Bordat, Kristýna Klanicová, Dominik Arbon, Farnaz Zahedifard, Anna Šipková, Eliška Drncová, Viktoriya Levytska, Jan Mach, Laura Plutowski-Wrobel and 9 more

Abstract read
In one paragraph

Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ronald MalychDepartment of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.
Yann BordatLPHI, University of Montpellier, CNRS, INSERM, Montpellier 34095, France.
Kristýna KlanicováDepartment of Organic Chemistry, Faculty of Science, Charles University, Prague 25250, Czech Republic.
Dominik ArbonDepartment of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.ORCID 0000-0002-2459-5446
Farnaz ZahedifardDepartment of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.
Anna ŠipkováDepartment of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.
Eliška DrncováDepartment of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.
Viktoriya LevytskaInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences, BC CAS, Branišovská 1160/31, České Budějovice 37005, Czech Republic.
Jan MachDepartment of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.
Laura Plutowski-WrobelCentre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany.
Marta MachadoCentre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany.
Jan ŠtursaLaboratory of Clinical Pathophysiology, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague 140 21, Czech Republic.
Jaroslav TruksaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic.
Markus GanterCentre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany.
Daniel SojkaInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences, BC CAS, Branišovská 1160/31, České Budějovice 37005, Czech Republic.
Martin ZoltnerDepartment of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.ORCID 0000-0002-0214-285X
Sébastien BesteiroLPHI, University of Montpellier, CNRS, INSERM, Montpellier 34095, France.
Lukáš WernerLaboratory of Clinical Pathophysiology, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague 140 21, Czech Republic.
Robert SutakDepartment of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.ORCID 0000-0001-5588-1683

Funding

ECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6M
NCI NIH HHS U10 CA021115
6 · The paper itself

Abstract

Parasitic protozoa exhibit a high demand for iron, with mitochondrial iron metabolism representing a vulnerable target for chemotherapeutic intervention. We recently demonstrated that mitochondrial targeting of the iron chelator deferoxamine (DFO) via triphenylphosphonium (TPP) conjugation enhances its antiparasitic efficacy. To expand upon this strategy, mitochondrially targeted derivatives of DFO and deferasirox (DFX) were synthesized and evaluated for their activity against important human parasites. The DFX derivative mitoDFX was effective against

Indexed as

Antiparasitic AgentsIron Chelating AgentsMitochondriaToxoplasmaTrypanosomaAnimalsDeferasiroxDeferoxamineDrug DesignHumansIronStructure-Activity RelationshipAntiparasitic AgentsDeferasiroxDeferoxamineIronIron Chelating Agentsantiparasitic agentsdrug repurposingiron chelatorsmitochondrionToxoplasmaTrypanosoma

Identifiers

PMID41428959
PMCPMC12797238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.